Poirier N C, Williams W G, Van Arsdell G S, Coles J G, Smallhorn J F, Omran A, Freedom R M
Division of Cardiovascular Surgery, Hospital for Sick Children, University of Toronto, 555 University Avenue, Suite 1525, ON M5G 1X8, Toronto, Canada.
Eur J Cardiothorac Surg. 2000 Jul;18(1):54-61. doi: 10.1016/s1010-7940(00)00402-4.
Left atrioventricular valve regurgitation (LAVVR) is the most frequent indication for reoperation following atrioventricular septal defect (AVSD) repair. We estimate from our experience that within 10 years of initial repair, 14% of patients undergoing repair of atrioventricular septal defect (AVSD) require reoperation for this complication. We have developed a novel leaflet augmentation technique for LAVVR which may avoid failure of conventional repair and/or the need for valve replacement.
The novel technique consists of insertion of a glutaraldehyde-treated autologous pericardial patch to augment the bridging leaflets of the atrioventricular valve. We describe the outcome of eight patients in whom this technique was used and compared them to 68 other patients with AVSD undergoing reoperation for LAVVR by either conventional repair (n=54) or valve replacement (n=14).
There were no early deaths or major complications following patch repair. The mean follow-up is 2.3 years (range 1-8.5 years) during which there were no late deaths. Two patients underwent reintervention at 3.5 and 5 years after patch repair for LAVVR and were successfully rerepaired. Mild residual LAVVR was seen at last echocardiography in six patients and mild to moderate in two. These results compare favorably with the 68 patients who underwent conventional surgery. The 3-year freedom from reoperation was 86% for both repair groups. Dysplastic valve tissue appears to be a major risk factor for failure of conventional repair or for valve replacement. Failure of conventional valve repair led to valve replacement in six of seven patients.
For patients with late LAVVR after AVSD repair, pericardial leaflet augmentation is durable and may avoid failure of conventional repair or valve replacement in patients with dysplastic valves.
左房室瓣反流(LAVVR)是房室间隔缺损(AVSD)修复术后再次手术最常见的指征。根据我们的经验估计,在初次修复后的10年内,14%的接受房室间隔缺损(AVSD)修复的患者因该并发症需要再次手术。我们开发了一种用于LAVVR的新型瓣叶增强技术,该技术可能避免传统修复失败和/或瓣膜置换的需要。
该新技术包括插入经戊二醛处理的自体心包补片以增强房室瓣的桥接瓣叶。我们描述了8例使用该技术的患者的结果,并将他们与另外68例因LAVVR接受再次手术的AVSD患者进行比较,后者分别接受传统修复(n = 54)或瓣膜置换(n = 14)。
补片修复后无早期死亡或重大并发症。平均随访2.3年(范围1 - 8.5年),在此期间无晚期死亡。2例患者在补片修复LAVVR后3.5年和5年接受再次干预,并成功再次修复。在最后一次超声心动图检查中,6例患者可见轻度残余LAVVR,2例为轻度至中度。这些结果优于接受传统手术的68例患者。两个修复组的3年再次手术自由度均为86%。发育异常的瓣膜组织似乎是传统修复失败或瓣膜置换的主要危险因素。传统瓣膜修复失败导致7例患者中的6例进行瓣膜置换。
对于AVSD修复术后发生晚期LAVVR的患者,心包瓣叶增强术效果持久,对于瓣膜发育异常的患者可能避免传统修复或瓣膜置换失败。